- Thinly traded micro cap Aldeyra Therapeutics (NASDAQ:ALDX) is up 6% premarket on modest volume in reaction to updated data from its allergen chamber clinical methods study evaluating topical ophthalmic solution reproxalap in patients with allergic conjunctivitis.
- The company says the aldehyde trap showed "highly statistically significant" activity compared to vehicle (placebo) across all assessed symptoms and signs in 70 subjects with ocular allergy to ragweed.
- Specifically, treatment with reproxalap resulted in statistically significant relative reductions in ocular itching, redness and tearing as well as total ocular symptom score. Both strengths (0.25% and 0.50%) were equally effective. The results were consistent with the outcome of the Phase 3 ALLEVIATE study announced in March.
- A Phase 3 trial, INVIGORATE, evaluating the 0.25% formulation should launch in H1 2020.
Aldeyra up 6% premarket on positive reproxalap data
Recommended For You
About ALDX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALDX | - | - |
Aldeyra Therapeutics, Inc. |